^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NRT-YHD_001

    i
    Other names: NRT-YHD_001
    Associations

    News

    Trials
    Company:
    Neornat
    Drug class:
    TSP1 stimulant
    Related drugs:
    Associations

    News

    Trials
    over1year
    In vivo therapeutic validation of NRT-YHD_001, a novel macrophage checkpoint inhibitor, in liver cancer (AACR 2023)
    As a result, the NRT-YHD_001 administration group showed significant therapeutic effect compared to sorafenib. These results showed that NRT-YHD_001 had a strong anticancer effect by converting the macrophage of don't eat me into eat me signal in the tumor microenvironment of liver cancer, thereby removing or inhibiting liver cancer cells.Keywords: let-7i-5p, macrophage, phagocytosis, liver cancer, NRT-YHD_001
    Preclinical • Checkpoint inhibition
    |
    THBS1 (Thrombospondin 1) • SIRPA (Signal Regulatory Protein Alpha)
    |
    THBS1 expression
    |
    sorafenib • NRT-YHD_001